Miracle drug’ can cost Rs 13 lakh for haemophilia A patient annually, but reduced dose found efficacious & cost-effective in ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

A new study found that patients with hemophilia A could safely switch directly from emicizumab to Mim8 without a washout period, meaning they did not need to stop treatment before starting the new ...

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and ...

Novo Nordisk NVO announced new data from the phase III FRONTIER clinical program, comprising five separate studies evaluating ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, ...

Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi (marstacimab) for adults and adolescents with haemophilia A or B with inhibitors. The ...

Pfizer Inc. (NYSE:PFE) announced encouraging results from its Phase 3 clinical trial of HYMPAVZI, a potential new treatment ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

Low dose of emicizumab could be as effective as standard dose against Haemophilia A, according to a study led by the Indian ...